In the log-rank test, an elevated HER2 ECD level (i.e., >15.2 ng/ml) was of prognostic value in terms of DMFS, irrespective of tumor size, hormone-receptor status, and anti-HER2 therapy (Figure 4B,D,F). Here, ERBB2 is linked to neoplasm.